Intraperitoneal Topoisomerase‐I Inhibitors: Preliminary Findings with 9‐Aminocamptothecin

Franco M. Muggia(NYU Langone Health), Heather Wasserstrom(Eli Lilly (United States)), Joan Sorich, Leonard Liebes(New York University), M Potmĕsil(New York University), Gila Hornreich(New York University), Anne Hamilton(Royal Women's Hospital), Andrea Downey(University of New Mexico), Howard S. Höchster(Rutgers, The State University of New Jersey)
Annals of the New York Academy of Sciences
December 1, 2000
10.1111/j.1749-6632.2000.tb07036.x
Cited by 4

Related Papers

Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391